According to Lineage Cell Therapeutics 's latest financial reports the company's current EPS (TTM) is -$0.23. In 2022 the company made an earnings per share (EPS) of -$0.27 an increase over its 2021 EPS that were of -$0.47.
Year | EPS | Change |
---|---|---|
2023 (TTM) | -$0.21 | -20.63% |
2022 | -$0.27 | -42.31% |
2021 | -$0.47 | 85.71% |
2020 | -$0.25 | 250% |
2019 | -$0.07197 | -88.57% |
2018 | -$0.63 | 105.88% |
2017 | -$0.31 | -153.13% |
2016 | $0.58 | -154.24% |
2015 | -$1.06 | 5.36% |
2014 | -$1.01 | -30.86% |
2013 | -$1.46 | 88.37% |
2012 | -$0.77 | 19.44% |
2011 | -$0.65 | 33.33% |
2010 | -$0.49 | 68.75% |
2009 | -$0.29 | -5.88% |
2008 | -$0.31 | 183.33% |
2007 | -$0.11 | -25% |
2006 | -$0.14 | -27.27% |
2005 | -$0.20 | -38.89% |
2004 | -$0.32 | 38.46% |
2003 | -$0.23 | -43.48% |
2002 | -$0.41 | -26.63% |
2001 | -$0.56 | -28.75% |
2000 | -$0.79 | -13.73% |
1999 | -$0.92 | |
1997 | -$0.59 | 3.13% |
1996 | -$0.58 |